StockNews.com Downgrades Kamada (NASDAQ:KMDA) to Buy

Kamada (NASDAQ:KMDA) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.

A number of other equities analysts also recently commented on the stock. Benchmark initiated coverage on shares of Kamada in a report on Friday. They issued a “buy” rating and a $15.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Kamada in a research report on Thursday, March 6th.

Kamada Stock Performance

Kamada stock traded down $0.02 during mid-day trading on Tuesday, reaching $7.08. 61,393 shares of the company were exchanged, compared to its average volume of 78,691. Kamada has a 12-month low of $4.74 and a 12-month high of $9.16. The business has a fifty day moving average of $7.19 and a 200 day moving average of $6.28. The firm has a market cap of $406.96 million, a P/E ratio of 25.29, a PEG ratio of 0.97 and a beta of 0.97.

Hedge Funds Weigh In On Kamada

Several hedge funds and other institutional investors have recently modified their holdings of KMDA. Public Employees Retirement System of Ohio acquired a new position in Kamada during the 3rd quarter valued at approximately $77,000. JPMorgan Chase & Co. purchased a new stake in shares of Kamada during the fourth quarter valued at $67,000. NewEdge Advisors LLC increased its position in shares of Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 8,260 shares during the period. Aristides Capital LLC increased its position in shares of Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares during the period. Finally, Geode Capital Management LLC raised its stake in Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after acquiring an additional 1,549 shares during the last quarter. 20.38% of the stock is owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.